Every Form 4 that Veracyte, Inc. (VCYT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VCYT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCYT filings page.
Veracyte, Inc. (VCYT) director stock sale reported in a Form 4 filing. A company director filed as a single reporting person and disclosed three open‑market sales of Veracyte common stock on 11/20/2025, all coded as sales. The transactions, made pursuant to a Rule 10b5-1 plan adopted on August 21, 2025, involved 1,491 shares at a weighted average price of $40.9526, 7,049 shares at a weighted average price of $42.4765, and 1,460 shares at a weighted average price of $43.2095.
After these sales, the reporting person beneficially owned 27,199 shares of Veracyte common stock, held directly. The filing notes that each weighted average price represents multiple trades within specified price ranges, and more detailed breakdowns are available to the SEC, the issuer, or a shareholder upon request.
Veracyte (VCYT) insider activity: The company’s VP and Chief Accounting Officer reported open‑market sales of common stock. On 11/07/2025, 5,818 shares were sold at a weighted average price of $40.2078. On 11/10/2025, 5,102 shares were sold at a weighted average price of $42.3321. Following these transactions, beneficial ownership stood at 38,745 shares.
The filing notes that each weighted average reflects multiple trades within disclosed price ranges, with detailed breakdowns available upon request.
Veracyte (VCYT) reported an insider transaction by its SVP, General Counsel. On 11/05/2025, the officer sold 6,466 shares of common stock at $40 per share, coded as an open market sale (S). Following the sale, the reporting person beneficially owned 82,973 shares, held directly. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2024.
Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the insider exercised stock options for 30,000 shares at exercise prices of $5.28, $7.94, and $7.60, then sold 43,196 shares in multiple trades at weighted average prices ranging from $41.10 to $46.40. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2024.
Following the transactions, the insider directly beneficially owns 30,468 shares. The options exercised were fully vested, tied to grants expiring on 06/20/2026, 06/07/2027, and 06/07/2028.
Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the reporting person sold 9,674 shares of common stock, coded “S”. The weighted average sale price was $40.0239, with individual trades ranging from $40.00 to $40.70.
Following the sale, the insider beneficially owned 13,554 shares, held directly. The transactions were made under a Rule 10b5-1 trading plan adopted on August 20, 2024, which pre‑sets trading instructions.
Veracyte, Inc. (VCYT) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 7,000 shares of common stock at $41 on 11/05/2025, marked with transaction code S. The filing notes the trades were made under a Rule 10b5-1 plan adopted on August 13, 2024.
After the sale, the officer beneficially owns 126,158 shares, held directly.
Veracyte, Inc. (VCYT) officer Jonathan Wygant, VP and Chief Accounting Officer, reported an equity award on Form 4. On 10/28/2025, he acquired 2,886 shares of common stock at $0 under transaction code A, reflecting a restricted stock unit grant. Following the transaction, his beneficial ownership stands at 49,665 shares, held directly.
The filing notes the RSUs were awarded on October 28, 2025 and vest in full on the first anniversary of the grant date, subject to his continued employment.
Veracyte, Inc. insider Phillip G. Febbo sold 8,349 shares of common stock on 10/06/2025 at a weighted average price of $36.0174, reducing his beneficial ownership to 92,441 shares. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on 09/04/2024, and individual sale prices ranged from $35.82 to $36.28. The Form 4 was signed by an attorney-in-fact on 10/07/2025. No options or derivative transactions were reported.
Veracyte (VCYT) insider transaction: The company’s Chief Commercial Officer-CLIA reported a sale of 2,539 shares of common stock at $35 on 10/01/2025, coded “S”. The filing notes the trades were made under a Rule 10b5-1 plan adopted on June 9, 2025. Following the transaction, the reporting person beneficially owns 89,099 shares, held directly.
Robert S. Epstein, a director of Veracyte, Inc. (VCYT), reported transactions on a Form 4 dated 10/01/2025. He exercised 10,000 stock options with an exercise price of $7.94, resulting in 10,000 shares issued, and subsequently sold 21,473 common shares at a weighted average sale price of $35.0768 (individual sales ranged $35.00–$35.30). The Form shows his beneficial ownership changing from 83,919 shares after the option exercise to 62,446 shares following the sale. The transactions were made under a Rule 10b5-1 plan adopted June 5, 2025, and the Form was signed by an attorney-in-fact on 10/03/2025.
An officer of Veracyte, Inc. executed a programmed sale of 2,160 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan. The sale's weighted average price was approximately $35.00 per share (individual prices ranged $35.00–$35.05), and the reporting person retained beneficial ownership of 89,439 shares after the transactions. The filer notes the sales were made pursuant to a plan adopted on 9/04/2024, and that detailed per-price share counts are available on request.
Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported the sale of 2,283 shares of Veracyte common stock on 09/19/2025 under a pre-established Rule 10b5-1 plan adopted on 09/04/2024. The filing shows a weighted-average sale price of $33.6923 per share, with individual sale prices ranging from $33.50 to $34.00. After the transaction, Ms. McGuire beneficially owned 91,599 shares, reported as direct ownership.
The Form 4 was executed by an attorney-in-fact and explicitly states the sale was made pursuant to the 10b5-1 plan; additional per-price share breakdowns are available on request to the SEC, the issuer, or a shareholder.